JP2019502741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502741A5 JP2019502741A5 JP2018538604A JP2018538604A JP2019502741A5 JP 2019502741 A5 JP2019502741 A5 JP 2019502741A5 JP 2018538604 A JP2018538604 A JP 2018538604A JP 2018538604 A JP2018538604 A JP 2018538604A JP 2019502741 A5 JP2019502741 A5 JP 2019502741A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 9
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 9
- 208000021039 metastatic melanoma Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022034549A JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281962P | 2016-01-22 | 2016-01-22 | |
| US62/281,962 | 2016-01-22 | ||
| PCT/US2017/014578 WO2017127811A1 (en) | 2016-01-22 | 2017-01-23 | Methods for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022034549A Division JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019502741A JP2019502741A (ja) | 2019-01-31 |
| JP2019502741A5 true JP2019502741A5 (enExample) | 2020-12-24 |
Family
ID=59362109
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538604A Pending JP2019502741A (ja) | 2016-01-22 | 2017-01-23 | がんを処置するための方法 |
| JP2022034549A Abandoned JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022034549A Abandoned JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190030023A1 (enExample) |
| EP (1) | EP3405203A4 (enExample) |
| JP (2) | JP2019502741A (enExample) |
| CN (1) | CN108883132A (enExample) |
| CA (1) | CA3010617A1 (enExample) |
| WO (1) | WO2017127811A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3808748B1 (en) | 2016-06-21 | 2026-05-20 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| CA3066778A1 (en) * | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| SG11202007590TA (en) | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| JP2021521439A (ja) * | 2018-04-13 | 2021-08-26 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がん血清バイオマーカーおよびその使用方法 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3878446A1 (en) * | 2020-03-09 | 2021-09-15 | Universite De Geneve | Hsd11b1 inhibitors for use in immunotherapy and uses thereof |
| CN115515585A (zh) | 2020-03-10 | 2022-12-23 | X4 制药有限公司 | 用于治疗中性粒细胞减少症的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101431895A (zh) * | 2006-05-01 | 2009-05-13 | 卡普里康制药公司 | 新颖的曲坦制剂和制备它们的方法 |
| KR20090013827A (ko) * | 2006-06-12 | 2009-02-05 | 화이자 프로덕츠 인크. | Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제 |
| CA2706292A1 (en) * | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| MX428954B (es) * | 2013-03-15 | 2025-11-13 | Univ Pennsylvania | Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana. |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| EA201690912A1 (ru) * | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| CN106456628A (zh) * | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| DK3552615T3 (da) * | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| US20180179282A1 (en) * | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| CN109069426B (zh) * | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
-
2017
- 2017-01-23 EP EP17742110.4A patent/EP3405203A4/en not_active Withdrawn
- 2017-01-23 CA CA3010617A patent/CA3010617A1/en active Pending
- 2017-01-23 JP JP2018538604A patent/JP2019502741A/ja active Pending
- 2017-01-23 WO PCT/US2017/014578 patent/WO2017127811A1/en not_active Ceased
- 2017-01-23 US US16/070,991 patent/US20190030023A1/en not_active Abandoned
- 2017-01-23 CN CN201780007245.9A patent/CN108883132A/zh active Pending
-
2022
- 2022-03-07 JP JP2022034549A patent/JP2022082565A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510785A5 (enExample) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| Tabchi et al. | Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab | |
| CN107427502A (zh) | 使用川地匹坦的治疗方法 | |
| JP2012522837A5 (enExample) | ||
| ES2904365T3 (es) | Administración conjunta de esteroides y ácido zoledrónico para prevenir y tratar la osteoartritis | |
| CN104203232A (zh) | 用于抗肿瘤试剂施用的方法 | |
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2017526695A5 (enExample) | ||
| JP2012533595A5 (enExample) | ||
| Kim et al. | Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer | |
| CA3113468A1 (en) | Grapiprant unit dosage forms | |
| Sirachainan et al. | Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy | |
| Xie et al. | Pilot postoperative ileus study of escin in cancer patients after colorectal surgery | |
| FI3777842T3 (fi) | Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi | |
| JP2016014051A (ja) | ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置 | |
| JP2024523123A (ja) | 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用 | |
| CN104434948B (zh) | 一种抗胰腺癌的药物组合物及其应用 | |
| AU2015242786B2 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| JP2015515971A5 (enExample) | ||
| Regueiro et al. | P78 upadacitinib maintenance therapy in moderate-to-severe Crohn’s disease: final results from the phase 3 U-ENDURE study | |
| Biyi et al. | Muscular visualisation on a bone scan in paraneoplastic dermatomyositis associated with breast cancer | |
| Shariff | Recent advancement and future perspective for the treatment of multidrug-resistant tuberculosis | |
| Ferslew et al. | P-177 safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Jak inhibitor TD-1473 after single and multiple oral doses in healthy subjects | |
| Mukohara et al. | 421 POSTER Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour |